The effects of mesoporphyrin on experimental arthritis in mice

Inflammation Research

Volumn 45, Issue 6, 1996, Pages 293-298

  Nagai, H ^a   Takaoka, Y ^a   Mori, H ^a   Matsuura, N ^b  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Collagen induced arthritis; Mesoporphyrin; Superantigen; T cell

Indexed keywords

COLLAGEN TYPE 2; INTERLEUKIN 2 RECEPTOR; MESOPORPHYRIN; PREDNISOLONE; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG STRUCTURE; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; SHEEP ERYTHROCYTE; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD4; ARTHRITIS; COLLAGEN; DISEASE MODELS, ANIMAL; ENTEROTOXINS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE ACTIVATION; MALE; MESOPORPHYRINS; MICE; MICE, INBRED DBA; PREDNISOLONE; RECEPTORS, INTERLEUKIN-2; REFERENCE STANDARDS; STAPHYLOCOCCUS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 0029893396     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02280994     Document Type: Article

References (33)

1. Wooley PH, Luthra HS, David CS. Type II collagen induced arthritis in mice. I. Major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
2. Stuart JM, Townes AS, Kang AH. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest 1982;69:673-83.
3. Stuart JM, Cremer MA, Kang AN, et al. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG antibodies can cause arthritis. J Exp Med 1982;155:1-16.
4. Niver P, Susan H, Orzechowski RF, et al. Humoral and cellular immunologic aspects of adjuvant and collagen arthritis in rats. J Immunopharmacol 1986;8:347-70.
5. Mccune WJ, Trenthmam DE, David JR. Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen-induced arthritis. Arthr Rheum 1980;23: 295-306.
6. Dynesiums-trentham RA, Rowland D, Trentham DE, et al. Rat leukocyte inhibitory factor. Similarities to human LIF and generation by cells from rats with collagen-induced arthritis. Cell Immunol 1981;63:362-73.
7. Holmdahl R, Klareskog L Wigzell H, et al. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II specific T-cell lines and clones. Scand J Immunol 1985;22:295-306.
8. Trentham DE, Dynesius RA, David JR. Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Exp Invest 1978;62:359-366.
9. Kakimoto K, Nakamura T, Onoue K, et al. The effect of antiddhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 1992;142:326-37.
10. Takeoka Y, Naiki M, Suehiro S, et al. 2-Buten-4-Olide (2-B4O) inhibits type II collagen-induced arthritis in Lewis rats. Int J Immunopharmac 1993;15:803-10.
11. Fuchigami H, Nishimura T, Kimura K, et al. Effect of actarit on type II collagen-induced arthritis in mice. Arzneim Forsch Drug Res 1994;44:64-8.
12. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995;92:517-21.
13. Herzog C, Walker C, Müller W, et al. Monoclonal anti-CD4 in arthritis. Lancet 1987;11:1461-2.
14. Herzog C, Walker C, Pichler WJ, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and criculating T cells. J Autoiummunol 1989;2:627-42.
15. Goldberg D, Morel P, Bach J, et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmunol 1991;4:617-30.
16. Horneff G, Burmester GR, Kalden JR, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthr Rheum 1991;34:129-40.
17. Wendung D, Wijdenes J, Morel-Fourrier, et al. Therapeutic use of minoclonal anti CD4 antibody in rheumatoid arthritis. J Rheumatol 1991;18:325-7.
18. Reiter C, Kakavand B, Krüger K, et al. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthr Rheum 1991;34:525-36.
19. Kirkham BW, Pitzalis C, Panayi GS, et al. Monoclonal antibody treatment in rheumatoid arthritis. The clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1001;30:459-63.
20. Choy EHS, Chikanza IC, Panati GS, et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
21. Lubbe PA, Reiter C, Riethmuller G, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthr Rheum 1993;36:1375-9.
22. Weinblatt ME, Coblyn JS, Austen KF, et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthr Rheum 1987;30:11-7.
23. Yocum DE, Klippel JH, Dougherty S, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomizied study. Ann Intern Med 1988;109:863-9.
24. Stepien H, Kunert-Radek J, Pawlikowski M, et al. Inhibitory effect of porphyrins on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun 1991;174:313-22.
25. Yen A, Gigli I, Barret KE. Dual effects of protoporphyrin and long wave ultraviolet light on histamine release from rat peritoneal and cutaneous mast cells. J Immunol 1990;144:4327-32.
26. Musser MA, Fiel RJ. Cutaneous photosensitizing and immunosuppressive effects of a series of tumor localizing porphyrins. Photochem Photobiol 1991;55:119-23.
27. Nagai H, Nishiyori T, Daikoku M, et al. Immunopharmacological studies of sodium copper chlorphyllin. Jpn J Pharmacol 1983;33:819-28.
28. Nagai H, Kitagaki K, Kuwabara K, et al. Anti-inflammatory properties of zinc protoporphyrin disodium. Agents Actions 1992;37:273-83.
29. Courtenay JS, Pullman MJ, Mosdale B, et al. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
30. Trentham DE, Dynesius-trentham RA. Attenuation of an adjuvant arthritis by type 11 collagen. J Immunol 1983;130: 2689-92.
31. Nagai H, Takaoka Y, Mori H, et al. The model of arthritis induced by superantigen. Life Science 1994;55:PL 233-57.
32. Lagrange PH, Mackaness GB, Miller TE. Influence of dose and route of antigen injection on the immunological of T cells. J Exp Med 1974;139:528-42.
33. Silverman ED, Isacovics B, Laxer RM, et al. Synovial fluid cells in juvenile arthritis. Evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol 1993;91:90-5.